$1.65
0[0.00%]
Last update: 4:20PM Get Real Time Here
Reneo Pharmaceuticals
(NASDAQ:RPHM)Reneo Pharmaceuticals Stock (NASDAQ:RPHM), Analyst Ratings, Price Targets, Predictions
Reneo Pharmaceuticals Inc has a consensus price target of $17.39, established from looking at the 18 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Jefferies, and Leerink Partners on December 15, 2023. With an average price target of $1.43 between HC Wainwright & Co., Jefferies, and Leerink Partners, there's an implied -13.13% downside for Reneo Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Jefferies
Leerink Partners
William Blair
HC Wainwright & Co.
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Reneo Pharmaceuticals
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 12/15/2023 | RPHM | Buy Now | Reneo Pharmaceuticals | $1.65 | -9.09% | HC Wainwright & Co. | Mitchell Kapoor | $30 → $1.5 | Downgrade | Buy → Neutral | Get Alert |
| 12/15/2023 | RPHM | Buy Now | Reneo Pharmaceuticals | $1.65 | 9.09% | Jefferies | Eun Yang | $17 → $1.8 | Downgrade | Buy → Hold | Get Alert |
| 12/15/2023 | RPHM | Buy Now | Reneo Pharmaceuticals | $1.65 | -39.39% | Leerink Partners | Joseph Schwartz | → $1 | Downgrade | Outperform → Market Perform | Get Alert |
| 11/15/2023 | RPHM | Buy Now | Reneo Pharmaceuticals | $1.65 | — | William Blair | Myles Minter | — | Initiates | → Outperform | Get Alert |
| 11/14/2023 | RPHM | Buy Now | Reneo Pharmaceuticals | $1.65 | 1718.18% | HC Wainwright & Co. | Mitchell Kapoor | → $30 | Reiterates | Buy → Buy | Get Alert |
| 10/12/2023 | RPHM | Buy Now | Reneo Pharmaceuticals | $1.65 | 1718.18% | HC Wainwright & Co. | Mitchell Kapoor | → $30 | Reiterates | Buy → Buy | Get Alert |
| 09/08/2023 | RPHM | Buy Now | Reneo Pharmaceuticals | $1.65 | 1718.18% | HC Wainwright & Co. | Gobind Singh | → $30 | Reiterates | Buy → Buy | Get Alert |
| 08/28/2023 | RPHM | Buy Now | Reneo Pharmaceuticals | $1.65 | 1718.18% | HC Wainwright & Co. | Gobind Singh | → $30 | Initiates | → Buy | Get Alert |
| 07/03/2023 | RPHM | Buy Now | Reneo Pharmaceuticals | $1.65 | 1293.94% | B of A Securities | Jason Zemansky | → $23 | Initiates | → Buy | Get Alert |
| 09/19/2022 | RPHM | Buy Now | Reneo Pharmaceuticals | $1.65 | 1778.79% | HC Wainwright & Co. | Gobind Singh | → $31 | Assumes | → Buy | Get Alert |
| 05/18/2022 | RPHM | Buy Now | Reneo Pharmaceuticals | $1.65 | 990.91% | Piper Sandler | Yasmeen Rahimi | $45 → $18 | Maintains | Overweight | Get Alert |
| 03/24/2022 | RPHM | Buy Now | Reneo Pharmaceuticals | $1.65 | 809.09% | SVB Leerink | Joseph Schwartz | $25 → $15 | Maintains | Outperform | Get Alert |
| 01/27/2022 | RPHM | Buy Now | Reneo Pharmaceuticals | $1.65 | 1596.97% | Baird | Brian Skorney | → $28 | Initiates | → Outperform | Get Alert |
| 12/21/2021 | RPHM | Buy Now | Reneo Pharmaceuticals | $1.65 | 1596.97% | HC Wainwright & Co. | Edwin Zhang | → $28 | Initiates | → Buy | Get Alert |
| 11/22/2021 | RPHM | Buy Now | Reneo Pharmaceuticals | $1.65 | 2627.27% | Ladenburg Thalmann | Matthew Kaplan | — | Initiates | → Buy | Get Alert |
| 05/04/2021 | RPHM | Buy Now | Reneo Pharmaceuticals | $1.65 | 1415.15% | SVB Leerink | Joseph Schwartz | — | Initiates | → Outperform | Get Alert |
| 05/04/2021 | RPHM | Buy Now | Reneo Pharmaceuticals | $1.65 | 1354.55% | Jefferies | Eun Yang | — | Initiates | → Buy | Get Alert |
| 05/04/2021 | RPHM | Buy Now | Reneo Pharmaceuticals | $1.65 | 2627.27% | Piper Sandler | Yasmeen Rahimi | — | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for Reneo Pharmaceuticals (RPHM)?
The latest price target for Reneo Pharmaceuticals (NASDAQ: RPHM) was reported by HC Wainwright & Co. on December 15, 2023. The analyst firm set a price target for $1.50 expecting RPHM to fall to within 12 months (a possible -9.09% downside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Reneo Pharmaceuticals (RPHM)?
The latest analyst rating for Reneo Pharmaceuticals (NASDAQ: RPHM) was provided by HC Wainwright & Co., and Reneo Pharmaceuticals downgraded their neutral rating.
When was the last upgrade for Reneo Pharmaceuticals (RPHM)?
There is no last upgrade for Reneo Pharmaceuticals.
When was the last downgrade for Reneo Pharmaceuticals (RPHM)?
The last downgrade for Reneo Pharmaceuticals Inc happened on December 15, 2023 when HC Wainwright & Co. changed their price target from $30 to $1.5 for Reneo Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Reneo Pharmaceuticals (RPHM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Reneo Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Reneo Pharmaceuticals was filed on December 15, 2023 so you should expect the next rating to be made available sometime around December 15, 2024.
Is the Analyst Rating Reneo Pharmaceuticals (RPHM) correct?
While ratings are subjective and will change, the latest Reneo Pharmaceuticals (RPHM) rating was a downgraded with a price target of $30.00 to $1.50. The current price Reneo Pharmaceuticals (RPHM) is trading at is $1.65, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.